JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Pharmaceuticals	283.65M	158.22M	173.86M	145.70M	30.80M
Pharmaceuticals Growth	79.28%	-8.99%	19.32%	373.10%	-
Total	283.65M	158.22M	173.86M	145.70M	30.80M
Total Growth	79.28%	-8.99%	19.32%	373.10%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
People's Republic of China (PRC)	283.65M	158.22M	173.86M	145.70M	30.80M
People's Republic of China (PRC) Growth	79.28%	-8.99%	19.32%	373.10%	-
Total	283.65M	158.22M	173.86M	145.70M	30.80M
Total Growth	79.28%	-8.99%	19.32%	373.10%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 7, 2026

Data Sources Report a data error